1-4 of 4
Cassie Zimmerman, MA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Cassie Zimmerman, MA, Elias Jabbour, MD, Molly D. Greenberg, B.S., Sangmin Lee, MD, Alan F List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Rami S Komrokji, MD
Journal: Blood
Blood (2014) 124 (21): 3273.
https://doi.org/10.1182/blood.V124.21.3273.3273
Published: 2014
Journal Articles

The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

Aziz Nazha, MD, Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, John Barnard, Cassie Zimmerman, MA, Al Ali Najla, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Elias Jabbour, MD, Sangmin Lee, MD, Molly D. Greenberg, B.S., Alan F List, MD, Hagop M. Kantarjian, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS
Journal: Blood
Blood (2014) 124 (21): 3275.
https://doi.org/10.1182/blood.V124.21.3275.3275
Published: 2014
Journal Articles

Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS)

Connie Cheng, PharmD, Caitlin Siebenaller, PharmD, Paul Elson, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Kristin Colaluca, RN, Betty K. Hamilton, MD, Sean Hobson, MA, Matt E. Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Sudipto Mukherjee, MD MPH, Gin Rupp, RN, Cassie Zimmerman, MA, Mikkael A. Sekeres, MD MS, Aaron T. Gerds, MD MS
Journal: Blood
Blood (2014) 124 (21): 1933.
https://doi.org/10.1182/blood.V124.21.1933.1933
Published: 2014
Journal Articles

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Amer M. Zeidan, MBBS, MHS, Mikkael A. Sekeres, MD MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Cassie Zimmerman, MA, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Elias Jabbour, MD, Hagop Kantarjian, MD, Katrina Zell, Quiqing Wang, Steven D Gore, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Rami S Komrokji, MD
Journal: Blood
Blood (2014) 124 (21): 1935.
https://doi.org/10.1182/blood.V124.21.1935.1935
Published: 2014